Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8681573 | Brain Stimulation | 2017 | 33 Pages |
Abstract
DBS is far from being evident as a possible future therapeutic avenue for patients with DoC. Double-blind studies are lacking, and many clinical and ethical issues have to be addressed. In the rare cases when DBS for patients with DoC is considered, this needs to be evaluated meticulously on a case by case basis, with comprehensive overall outcome measures including psychological and quality-of-life assessments, and with the guidance of an ethical and interdisciplinary panel, especially in relation to proxy consent.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Jonathan Vanhoecke, Marwan Hariz,